Which genetic abnormalities are indicators of a poor prognosis for acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Genetic abnormalities that convey adverse risk are as follows:

  • t(6;9)(p23;q34.1); DEK- NUP214
  • t(v;11q23.3); KMT2A rearranged
  • t(9;22)(q34.1;q11.2); BCR- ABL1
  • inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)
  • −5 or del(5q); −7; −17/abn(17p)
  • Complex karyotype or monosomal karyotype
  • Wild-type NPM1 and high allelic ratio FLT3-ITD
  • Mutated RUNX1
  • Mutated ASXL1
  • Mutated TP53

Note that neither mutated RUNX or mutated ASXL1 should be used as an adverse prognostic marker if it occurs together with favorable-risk AML subtypes. [26]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!